Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2021 Jun 1

PMID 34060258

Authors

Yeo Wool Kang

Yang Hyun Baek

Sung Wook Lee

Sung Jae Park

Jun Sik Yoon

Ki Tae Yoon

Youngmi Hong

Nae Yun Heo

Kwang Il Seo

Sang Soo Lee

Hyun Chin Cho

Jung Woo Shin

Affiliations

Soon will be listed here.

Abstract

Background: The advancement of treatment with direct-acting antiviral (DAA) agents has improved the cure rate of hepatitis C virus (HCV) infection close to 100%. The aim of our study was to assess the real-world effectiveness and safety of DAA regimens for the treatment of patients with chronic HCV genotype 2.

Methods: We retrospectively analyzed the clinical data of patients treated with sofosbuvir plus ribavirin (SOF + RBV) or glecaprevir/pibrentasvir (G/P) for chronic HCV genotype 2 infection at seven university hospitals in the Korean southeast region.

Results: SOF + RBV therapy produced an 89% and 98.3% sustained virologic response 12 week (SVR12) after treatment completion in the full analysis set and per-protocol set, respectively, and the corresponding values for G/P therapy were 89.5% and 99.2%, respectively. The difference between the treatments was probably because 6.2% (59/953) of patients in the SOF + RBV group did not complete the treatment and 9.8% (14/143) in the G/P group did not test HCV RNA after treatment completion. Adverse events (A/Es) were reported in 59.7% (569/953) and 25.9% (37/143) of the SOF + RBV and G/P groups, respectively. In the SOF + RBV group, 12 (1.26%) patients discontinued treatment owing to A/Es, whereas no patients discontinued treatment because of A/Es in the G/P group.

Conclusion: In both treatment groups, SVR was high when treatment was completed. However, there was a high dropout rate in the SOF + RBV group, and the dropout analysis showed that these were patients with liver cirrhosis (LC; 43/285, 15.1%), especially those with decompensated LC (12/32, 37.5%). Therefore, an early initiation of antiviral therapy is recommended for a successful outcome before liver function declines. Furthermore, patients with decompensated LC who are considered candidates for SOF + RBV treatment should be carefully monitored to ensure that their treatment is completed, especially those with low hemoglobin and high alanine transaminase.

References

Asselah T, Kowdley K, Zadeikis N, Wang S, Hassanein T, Horsmans Y . Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2017; 16(3):417-426. DOI: 10.1016/j.cgh.2017.09.027. View

Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F . Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014; 21(11):762-8. DOI: 10.1111/jvh.12312. View

Kim M, Kim B, Han K . Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol. 2013; 48(6):681-8. PMC: 3698419. DOI: 10.1007/s00535-013-0770-9. View

Wirth T, Manns M . The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol. 2016; 27(8):1467-74. DOI: 10.1093/annonc/mdw219. View

van der Meer A, Veldt B, Feld J, Wedemeyer H, Dufour J, Lammert F . Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308(24):2584-93. DOI: 10.1001/jama.2012.144878. View

Kao J, Chien R, Chang T, Peng C, Hu T, Lo G . A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int. 2016; 36(8):1101-7. PMC: 5071670. DOI: 10.1111/liv.13082. View

Kanda T, Imazeki F, Yokosuka O . New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010; 4(3):548-61. PMC: 2940000. DOI: 10.1007/s12072-010-9193-3. View

von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T . Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005; 129(2):522-7. DOI: 10.1016/j.gastro.2005.05.008. View

Liu C, Kao J . Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine. 2014; 9:2051-67. PMC: 4008289. DOI: 10.2147/IJN.S41822. View

10.

Kim D, Kim I, Jeong S, Cho Y, Lee J, Jin Y . A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int. 2013; 33(4):586-94. DOI: 10.1111/liv.12108. View

11.

Hengst J, Falk C, Schlaphoff V, Deterding K, Manns M, Cornberg M . Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. J Infect Dis. 2016; 214(12):1965-1974. DOI: 10.1093/infdis/jiw457. View

12.

Ji F, Yeo Y, Wei M, Ogawa E, Enomoto M, Lee D . Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol. 2019; 71(3):473-485. DOI: 10.1016/j.jhep.2019.04.017. View

13.

Prenner S, VanWagner L, Flamm S, Salem R, Lewandowski R, Kulik L . Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017; 66(6):1173-1181. PMC: 5776681. DOI: 10.1016/j.jhep.2017.01.020. View

14.

Verna E, Morelli G, Terrault N, Lok A, Lim J, Di Bisceglie A . DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol. 2020; 73(3):540-548. DOI: 10.1016/j.jhep.2020.03.031. View

15.

Forns X, Lee S, Valdes J, Lens S, Ghalib R, Aguilar H . Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017; 17(10):1062-1068. DOI: 10.1016/S1473-3099(17)30496-6. View

16.

Feld J, Jacobson I, Hezode C, Asselah T, Ruane P, Gruener N . Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015; 373(27):2599-607. DOI: 10.1056/NEJMoa1512610. View

17.

. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026. View

18.

Ghany M, Morgan T . Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2019; 71(2):686-721. PMC: 9710295. DOI: 10.1002/hep.31060. View

19.

Kao J . Hepatitis C virus infection in Taiwan: Past, present, and future. J Formos Med Assoc. 2015; 115(2):65-6. DOI: 10.1016/j.jfma.2015.06.012. View

20.

Ioannou G, Green P, Berry K . HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017; . PMC: 5837901. DOI: 10.1016/j.jhep.2017.08.030. View